News | Radiation Therapy | August 24, 2015

First Proton Treatments with RayStation and Mevion S250

Ackerman Cancer Center in Jacksonville, Fla., treats its first patient with the Mevion S250 and the RayStation treatment planning system

Mevion S250, proton therapy

On April 30, 2015, a major milestone was reached at Ackerman Cancer Center in Jacksonville, Fla., when the first patient was treated with the Mevion S250 and the RayStation treatment planning system. Ackerman Cancer Center is the first private, physician-owned practice to implement proton therapy.

The clinical patient treatment plans were created entirely in RayStation, RaySearch’s highly advanced treatment planning and dose tracking software platform, and delivered on the Mevion S250 Proton System. “Providing this kind of innovative technology in a private setting is something that we knew we could accomplish. We look forward to working with our partners, RaySearch and Mevion, well into the future to bring cutting edge treatments to our patients,” said Scot Ackerman, M.D., medical director of the center.

“The implementation of proton therapy in a private center really shows how far this technology has come and how accessible it can be,” said Marc Mlyn, president of RaySearch Americas, Inc. “We are pleased that the Mevion and RaySearch combined solution has led to such a successful effort so rapidly, and we are glad to be partners with Ackerman Cancer Center’s team of professionals.”

“While we have many clinical proton sites in the USA, Europe and soon Asia, it is very satisfying to see the first Mevion and RaySearch effort up and running. RayStation was developed to handle any type of delivery system, and we will continue to work in close collaboration with our partners to bring new and exciting technologies to our mutual customers”, said Johan Löf, CEO of RaySearch Laboratories AB.

The current version of RayStation supports all relevant proton treatment techniques such as Uniform Scanning, Double Scattering and PBS / IMPT.

For more information: www.AckermanCancerCenter.com

 

Related Content

IBA Releases Razor Nano Ionization Chamber
News | Proton Therapy | September 22, 2017
September 22, 2017 — IBA (Ion Beam Applications S.A.) announced the release of the Razor Nano Chamber, the smallest a
Penn Medicine Treats World's First Patient on Varian's Halcyon System
News | Radiation Therapy | September 22, 2017
September 22, 2017 — Varian Medical Systems announced a patient at Penn Medicine, with head & neck cancer, became
BrainLAB Announces FDA Clearance For Two New Indication-Specific Radiosurgery Software Applications
Technology | Treatment Planning | September 21, 2017
Brainlab announced that it has received U.S. Food and Drug Administration (FDA) clearance for Elements Spine SRS and...
Accuray Showcases CyberKnife and Radixact Systems at ASTRO 2017
News | Radiation Therapy | September 21, 2017
Accuray Inc. announced that data and first-hand experience with its advanced CyberKnife and Radixact Systems will be...
RayCare Oncology Information System Being Shown at ASTRO 2017
News | Radiation Therapy | September 20, 2017
RaySearch will be exhibiting its next-generation oncology information system (OIS) RayCare, among other highlights, at...
ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017
News | Radiation Therapy | September 19, 2017
Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition...
Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting
News | Radiation Therapy | September 19, 2017
September 19, 2017 — Elekta will highlight its Mosaiq Oncology...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Overlay Init